Biomerica Cuts Losses, Secures Financing as inFoods IBS Gains Medicare Traction
Event summary
- Fiscal 2026 net loss improved 24% to $3.8M as R&D expenses fell 23% with key programs nearing commercialization.
- Secured $2.23M financing post-year-end from B. Riley Principal Capital and board members, with no warrants issued.
- 100% of initial Medicare claims for inFoods IBS paid at full $300 CMS rate; expanding to 200+ physicians.
- Signed $1.75M CDMO agreement for proprietary IVD assays, leveraging existing FDA-licensed manufacturing capacity.
- First commercial order for H. pylori test from a major European lab chain, with follow-on reorders.
The big picture
Biomerica's improved financial footing comes as its inFoods IBS test gains Medicare reimbursement traction, a critical milestone for scaling commercial adoption. The $2.23M financing—without dilutive warrants—provides runway to capitalize on this momentum while B. Riley explores strategic alternatives. The company's shift from R&D to commercialization aligns with broader diagnostics industry trends toward value-based reimbursement models.
What we're watching
- Commercialization Pace
- Whether Biomerica can sustain the 17% Q4 sales growth as inFoods IBS expands Medicare billing.
- Strategic Options
- How B. Riley's evaluation of partnerships or business combinations will impact governance and valuation.
- Operational Leverage
- The pace at which CDMO agreements and H. pylori test orders improve manufacturing utilization.
Related topics